Urovant Sciences Stock Price, News & Analysis

UROV NASDAQ

Company Description

Urovant Sciences (NASDAQ: UROV) is a publicly traded medicinal and botanical manufacturing company in the Manufacturing sector.

UROV stock has gained 60.0% over the past year.

This page provides a comprehensive overview of UROV stock, including real-time price data, latest news, SEC filings, insider trading activity, financial highlights, upcoming events, and short interest trends.

Stock Performance

Chart

$—

0.00%

0.00

Last updated:

+60%

Performance 1 year

$0.0

Market Cap

32.7M

Shares outstanding

Urovant Sciences (UROV) stock. Over the past 12 months, the stock has gained 60.0%.

Latest News

View All

April 13, 2022

—

Urovant Sciences to Present Interim Data from Phase 2a Study of Potential Novel Gene Therapy, URO-902, and New Analyses of Data from Phase 3 EMPOWUR Extension Trial of GEMTESA® (vibegron) 75 mg at 2022 American Urological Association Annual Meeting

conferences clinical trial

March 7, 2022

—

Urovant Sciences Announces Positive Topline Results of Phase 2a Trial of its Potential Novel Gene Therapy, URO-902

clinical trial

December 20, 2021

—

Urovant Sciences Announces Publication in Advances in Therapy of Analyses of Patient-Perceived Meaningfulness of Improvement in Symptom Reduction for Overactive Bladder Patients Treated with GEMTESA® (vibegron) 75 mg

November 8, 2021

—

Urovant Sciences Announces Publication in Blood Pressure Monitoring of Positive Ambulatory Blood Pressure Study Results for GEMTESA® (vibegron) 75 mg in Overactive Bladder Patients

February 12, 2021

0.00%

Urovant Sciences Provides Merger Update and Reports Third Quarter Fiscal Year 2020 Results

acquisition earnings

February 11, 2021

-0.12%

Urovant Sciences Announces Progression of URO-902 Phase 2a Trial Following Positive Recommendation from the Data and Safety Monitoring Board

clinical trial

Urovant Sciences has 10 recent news articles. Of the recent coverage, 2 articles coincided with positive price movement and 2 with negative movement. Key topics include conferences, clinical trial, acquisition, earnings, fda approval. View all UROV news →

SEC Filings

View All

No SEC filings available for UROV.

Financial Highlights

View Full Financials

—

Revenue (TTM)

—

Net Income (TTM)

—

Diluted EPS (TTM)

—

Operating Cash Flow

—

Net Profit Margin

—

Oper. Profit Margin

Upcoming Events

Short Interest History

Last 12 Months

Days to Cover History

Last 12 Months

UROV Company Profile & Sector Positioning

Urovant Sciences (UROV) operates in the Medicinal and Botanical Manufacturing industry within the broader Manufacturing sector and is listed on the NASDAQ.